In Vitro Diagnostics Quality Controls Global Markets: Revenue Data for 2021-2023, Estimated Figures for 2024, and Projected CAGRs Through 2029

The global market for In Vitro diagnostics quality controls is expected to grow from $1.5 billion in 2024 and is projected to reach $2.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.8% during the forecast period of 2024 to 2029.

This report provides details about the market for in vitro diagnostics quality controls used in checking the in vitro diagnostic devices present in labs, clinics and hospitals. This report will also highlight the current and future market potentiality of in vitro diagnostics quality controls, with a detailed analysis of the competitive environment between companies. Drivers, restraints, opportunities, prevalence or incidence of chronic diseases, and a regulatory scenario assessment will be covered in the current report. The report includes market projections for 2029 and market shares for key players.

Based on test type, the market is segmented into immunodiagnostics, clinical chemistry, hematology and hemostasis, molecular diagnostics, microbiology, and others. Based on products and services, the market is categorized into quality control products, data management solutions and quality assurance services. Based on type of manufacturer, the market is segmented into third-party controls and OEM controls. Based on end users, the market is segmented into hospitals, diagnostic laboratories and academic institutions.

By geographical region, the market has been segmented into North America, Europe, Asia-Pacific, and Rest of the World. Detailed analyses of major countries such as the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, and GCC countries are covered within the regional segments. For market estimates, data will be provided for 2023 as the base year, with estimates for 2024 and forecast value for 2029.

Report Includes

40 data tables and 40 additional tables
An overview of the global market for in vitro diagnostics (IVD) quality controls
Analysis of global market trends, featuring revenue data for 2021-2023, estimated figures for 2024, and projected CAGRs through 2029
Evaluation of the current market’s size and revenue growth prospects, along with a market share analysis by test type, manufacturer, product/services, end user and region
Discussion of market drivers and restraints and other dynamics
Assessment of the regulatory landscape, including product recalls
Analysis of the key companies’ market shares, recent M&A activity, acquisitions, joint ventures, partnerships, and patents
Company profiles including Abbott, bioMerieux, F. Hoffmann-La Roche Ltd., Siemens Healthineers, and Thermo Fisher Scientific Inc.

Company Profiles

Abbott
BD
Biomerieux
Bio-Rad Laboratories Inc.
Bio-Techne
Danaher Corp.
F. Hoffmann-La Roche Ltd.
Microbiologics
Quidelortho Corp.
Siemens Heathnieers Ag
Sysmex Corp.
Thermo Fisher Scientific Inc.

Key Topics Covered:

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market and Technology Background

Introduction
Overview
Classification of In Vitro Diagnostics Elements
Importance of In Vitro Diagnostics Quality Control
Regulations
Regulation of IVD products in Different countries

Chapter 3 Market Dynamics

Market Drivers
Rise in the Aging Population and Dependency on Frequent Diagnosis Procedures
Rising Demand for Third-Party Quality Control Products
Rising Incidence of Chronic Disease Cases
Strengthening Clinical Laboratories
Improving the Quality of Point-of-Care Testing
Market Restraints
Challenges for Quality Control Product Packaging
Increases in Shipping Costs or Service Issues
Improper Operation and Maintenance of Laboratory Equipment and Consumables
Market Opportunities
Rise in Home Care Testing Devices
Demand for Point-of-Care (POC) Testing Units

Chapter 4 Emerging Technologies and Developments

Artificial Intelligence
Prioritizing Old IVD Techniques
Automating In-Vitro Diagnostic Devices
Emerging Trends in In Vitro Diagnostics
FDA Approval
Rise in Demand for Personalized Medicine

Chapter 5 Market Segmentation Analysis

Segmentation Breakdown
Market Breakdown by Test Type
Immunodiagnostics
Clinical Chemistry
Hematology
Molecular Diagnostics
Microbiology
Other Test Types
Market Breakdown by Type of Manufacturer
Third-party Controls
ODM Controls
Market Breakdown by Products and Services
Quality Control Products
Data Management Solutions
Quality Assurance Services
Market Breakdown by End User
Diagnostic Laboratories
Hospitals and Clinics
Point-of-Care Centers
Research Institutions
Other End Users
Geographic Breakdown
Market Analysis by Region
North America
Market Size and Forecast
U.S.
Canada
Mexico
Europe
Market Size and Forecast
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
Market Size and Forecast
Japan
China
India
Australia and New Zealand
Rest of Asia-Pacific
Rest of the World
Market Size and Forecast
Brazil
GCC Countries
Rest of the World Countries

Chapter 6 Competitive Intelligence

Introduction
Global Analysis of Company Market Ranking
Agreements, Collaborations and Partnerships
In Vitro Diagnostics Developments and Startups, 2021-2023

Chapter 7 Sustainability

Importance of ESG in the In Vitro Diagnostics Industry
ESG Practices in the In Vitro Diagnostics Industry
Environmental Performance
Social Performance
Governance Performance
Case Studies
Publisher Viewpoint

Chapter 8 Appendix

For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”